Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.
Windtree Therapeutics, Inc. (WINT) generates news across biotechnology, licensing, financing and corporate diversification activities. Company press releases highlight its evolution from a biotechnology focus into a diversified business with several divisions and an emphasis on becoming a revenue generating company. For followers of WINT news, this means updates can span drug development milestones, asset sales, licensing income opportunities, environmental services initiatives, fintech transactions and capital markets activity.
In the biotech arena, Windtree’s news flow has included interim data and scientific presentations for its cardiovascular drug candidate istaroxime and related SERCA2a activators, as well as decisions to adjust or terminate specific clinical studies based on resources and strategic priorities. The company has also reported on strengthening its patent estate for these cardiovascular assets and later announced an agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC while retaining rights to a share of future proceeds and transferring certain development payables.
Windtree’s communications also cover its acute pulmonary franchise, where a global license agreement for RDS treatments such as SURFAXIN, lyophilized lucinactant and AEROSURF may generate milestone and royalty payments if development and commercialization progress under the licensee. Additional news items describe corporate strategy decisions, including a focus on environmental services and other revenue generating businesses, a letter of intent to acquire CommLoan, Inc. in the fintech and commercial real estate lending technology space, and the outcome of stockholder votes supporting financing flexibility.
Investors tracking WINT-related headlines will also see coverage of financing arrangements, preferred stock conversions, equity line of credit structures, and the company’s exploration of a BNB cryptocurrency treasury strategy, as well as its transition from the Nasdaq Capital Market to over-the-counter trading. Bookmarking this news feed can help readers monitor how Windtree’s mix of biotech assets, licensing agreements and diversified business initiatives evolves over time.
Windtree Therapeutics (OTCID: WINT) announced the sale of its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC (SPH) on Dec. 23, 2025. Under the agreement Windtree retains a 20% economic interest in any future milestone, royalty or commercial net revenue SPH receives, including potential global AHF (acute heart failure) commercial revenue if approved.
Windtree will receive a $700,000 cash payment if SPH completes a financing that raises at least $10,000,000. Windtree also transfers certain cardiovascular development payables to SPH, removing those funding obligations from Windtree.
Windtree Therapeutics (OTCID: WINT) announced it has signed a letter of intent dated December 3, 2025 to acquire CommLoan, Inc., a revenue-generating fintech focused on commercial real estate loan origination.
CommLoan will become a subsidiary, retain key employees, and has received bridge financing from Windtree during the transition. Management highlighted CommLoan's proprietary database and software/AI tools as strategic assets to accelerate growth and streamline lending processes.
Windtree Therapeutics (OTCID: WINT) said it may receive up to $78.9 million in development, regulatory and commercial milestone payments plus up to low double‑digit royalties under a global amended and restated license agreement executed in August 2022 for its acute pulmonary franchise including SURFAXIN, lyophilized lucinactant and AEROSURF.
The license partner is responsible for all development and commercialization costs. Windtree said any milestone or royalty receipts would be non‑dilutive and timing/details of potential payments will be communicated in the future.
Windtree Therapeutics (OTCID: WINT) announced allowed patents for istaroxime in Canada (Application No. 3,130,261) and Mexico (Application No. MX/a/2021/010483), and a granted patent for a next-generation pure SERCA2a activator in Israel (Application No. 291412) on Nov 14, 2025.
The company states its cardiovascular patent estate now counts issued/allowed patents and pending applications for istaroxime, dual-mechanism SERCA2a activators, and pure SERCA2a activators, while pursuing partnerships and considering a Phase 3 program for istaroxime based on prior clinical signals of favorable renal outcomes and no increase in arrhythmias.
Windtree Therapeutics (OTCID: WINT) announced on November 13, 2025 that it signed a letter of intent with TESI (OTC: TESI) and will receive $7.5 million in cash and TESI securities under a recently executed termination agreement.
The companies had been pursuing a potential acquisition of Titan Environmental Services, a Michigan waste management business, but mutually agreed to end that process and release reciprocal surviving obligations. Windtree said it will refocus on other opportunities as part of its strategy to become a revenue-generating company.
Windtree Therapeutics (OTCID: WINT) announced stockholder approval of ten key proposals at their Special Stockholder Meeting on August 28, 2025. The company is pivoting towards environmental services and revenue generation, abandoning previously considered cryptocurrency treasury plans.
Key approvals include proposals for environmental services transactions aimed at revenue generation, and an increase in authorized shares from 125 million to 1 billion. The company plans to partner its biotech assets, potentially eliminating $8.8 million in R&D expenses from 2024 related to its cardiovascular program.
The strategic shift focuses on establishing the Windtree Environmental Services division with potential for profitability through future acquisitions.
Windtree Therapeutics (NASDAQ:WINT) announced that its drug candidate istaroxime has been selected for a plenary session presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025. The presentation will focus on interim data from the Phase 2 SEISMiC C study in cardiogenic shock patients.
The interim analysis of the first 20 patients showed promising results with no new safety concerns and no excess arrhythmias when combined with standard therapies. The drug's effects were consistent with previous studies, showing potential benefits for patients with low blood pressure due to heart failure. Notably, cardiogenic shock SCAI Stage C has a 20-30% in-hospital mortality rate.
Windtree Therapeutics (NASDAQ:WINT) has announced positive interim analysis results from its SEISMiC C Phase 2 study evaluating istaroxime in SCAI Stage C cardiogenic shock patients. The study demonstrated that istaroxime maintained its safety profile and showed consistent physiological improvements when combined with current standard treatments.
The global, placebo-controlled, double-blinded trial included sites across the U.S., Europe, and Latin America, building upon previous successful SEISMIC B study results. The interim analysis of the first 20 patients revealed no new safety concerns or excess arrhythmias when istaroxime was administered alongside standard therapies. The company plans to advance to a global Phase 3 trial based on these encouraging results.
Windtree Therapeutics (NASDAQ:WINT) has announced significant reductions in its preferred stock shares outstanding through conversion and redemption. The company achieved a 99.3% reduction in Series C Preferred Stock to just 19 shares and a 68.5% reduction in Series D Preferred Stock to 1,161 shares between April 15 and July 25, 2025.
The announcement comes alongside updates on Windtree's crypto treasury strategy, including a $60 million investment agreement with Build and Build Corp, with potential follow-on subscriptions of up to $140 million. The company has also secured commitments for up to $700 million for BNB acquisitions. Notably, BNB coin has appreciated by over 17% since the initial announcement of the crypto treasury agreement.
Investors redeemed approximately $2.3 million worth of preferred series C and D shares, which could have been converted into approximately 7.7 common shares, effectively limiting future dilution.
Windtree Therapeutics (NASDAQ:WINT) has secured up to $520 million in new funding to expand its BNB cryptocurrency treasury strategy. The funding consists of a $500 million equity line of credit (ELOC) and a $20 million stock purchase agreement with Build and Build Corp.
The company plans to allocate 99% of the proceeds from both agreements to acquiring BNB cryptocurrency. The ELOC implementation is contingent on stockholder approval to increase authorized shares of common stock. This strategic move represents Windtree's effort to diversify its treasury assets through blockchain-based digital currencies.
FAQ
What is the current stock price of Windtree Therapeutics (WINT)?
What is the market cap of Windtree Therapeutics (WINT)?
